Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2017
Event: Entry into Material Definitive Agreements and creation of direct financial obligations.
Key Financial Metrics and Transaction Details
The filing discloses a financing transaction rather than standard periodic financial results (revenue, profit, or cash flow). Key metrics related to the transaction include:
- Instrument: Two 8% Convertible Redeemable Junior Subordinated Promissory Notes.
- Counterparty: GS Capital Partners, LLC.
- Total Principal Amount: $320,000 (Two notes of $160,000 each).
- Interest Rate: 8% per annum (increases to 24% or the highest rate permitted by law upon an event of default).
- Maturity Date: July 24, 2018 (one year from issuance).
- Conversion Price: 62% of the lowest closing bid price of Common Stock for the ten trading days prior to conversion.
- Funding Structure:
- First Note: Funded with cash.
- Back-End Note: Initially paid for by an offsetting promissory note (Note Receivable) issued by GS Capital to the Company, due March 24, 2018. Cash funding is required prior to conversion.
Material Changes and Conditions
The filing details specific conditions and risks associated with the new debt instruments:
- Prepayment: The First Note may be prepaid at any time without penalty. The Back-End Note may not be prepaid.
- Cancellation Triggers:
- If the First Note is redeemed within the first six months, the Back-End Note is deemed cancelled.
- The Back-End Note and Note Receivable will be immediately cancelled if the Company's shares do not maintain a minimum trading price and aggregate dollar trading volume during the five days prior to funding.
- Default Provisions: Upon an event of default, principal and accrued interest become immediately due. Default interest accrues at 24% per annum. Certain defaults may trigger penalty and liquidated damage provisions.
Guidance, Outlook, and Risks
Management Commentary: The filing does not provide forward-looking guidance, revenue outlook, or management commentary on operational performance. The focus is strictly on the terms of the financing agreement.
Risks and Contingencies:
- Liquidity Risk: The Back-End Note is contingent on future cash funding and specific stock market performance (price and volume) to remain active.
- Dilution Risk: The conversion price is set at a significant discount (62%) to the market price, which could result in substantial dilution to existing shareholders upon conversion.
- Regulatory Exemption: The issuance was made pursuant to Section 4(a)(2) of the Securities Act, relying on the representation that the securities were acquired for investment purposes with no intent to distribute.
Investor Verification Checklist
- Verify the current trading price and volume of Propanc Biopharma, Inc. common stock to assess the likelihood of the Back-End Note funding conditions being met.
- Review the full text of the Securities Purchase Agreements (Exhibits 10.1 and 10.2) for specific definitions of "events of default" and liquidated damage provisions.
- Confirm the status of the Note Receivable due March 24, 2018, and whether the cash funding for the Back-End Note has been executed.
- Assess the potential dilution impact based on the 62% conversion discount relative to current market prices.